Related Experiment Video

Updated: Jul 15, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Chronic lymphocytic leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up

, M Hallek

    Annals of Oncology : Official Journal of the European Society for Medical Oncology
    |May 11, 2007
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
    10:18

    From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

    Published on: October 19, 2014

    Related Experiment Videos

    Last Updated: Jul 15, 2026

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
    09:02

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

    Published on: November 26, 2018

    From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
    10:18

    From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

    Published on: October 19, 2014

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    IPSS-M downstaging before transplantation does not improve the prognosis of patients with myelodysplastic neoplasms.

    Bone marrow transplantation·2026

    Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma-A Retrospective Multicenter Analysis.

    European journal of haematology·2024

    Consistent FFP2-masking as part of reducing viral respiratory infections on medical wards for allogeneic hematopoietic stem cell transplantation.

    Scientific reports·2024

    [Proposal for participation in intensive care and emergency medicine studies for patients unable to give informed consent (Cologne Model)].

    Medizinische Klinik, Intensivmedizin und Notfallmedizin·2023

    [Recurrent SARS-CoV-2 infections in immunodeficiency].

    Innere Medizin (Heidelberg, Germany)·2022

    Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.

    Blood·2022

    Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Thymic radiation is associated with worse outcomes in patients with NSCLC.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us